In the pipeline
Our pipeline is focused on research in therapeutic areas where we can accelerate the development of transformational, life-changing medicines for patients
- X
Our pipeline at a glance
Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
As of October 30, 2025
48
Compounds in development
40+
Disease areas being studied
In the Pipeline
{"categoryColor":"#595454","phase":[{"name":"Phase 1","value":"bms:phase/phase-1","desc":"1"},{"name":"Phase 2","value":"bms:phase/phase-2","desc":"2"},{"name":"Phase 3","value":"bms:phase/phase-3","desc":"3"},{"name":"Registration","value":"bms:phase/registration","desc":"Tag for Registration"}],"listings":[{"compoundname":"<p><b>milvexian<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/cardiovascular","subcategory":"bms:tumor/secondary-stroke-prevention--","registrationstatus":""},{"compoundname":"<p><b>milvexian<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/cardiovascular","subcategory":"bms:tumor/acute-coronary-syndrome--","registrationstatus":""},{"compoundname":"<p><b>milvexian<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/cardiovascular","subcategory":"bms:tumor/atrial-fibrillation--","registrationstatus":""},{"compoundname":"<p><b>MYK-224<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-2","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/cardiovascular","subcategory":"bms:tumor/heart-failure-with-preserved-ejection-fraction","registrationstatus":""},{"compoundname":"<p><b>arlo-cel<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-2","researcharea":"<p>Multiple Myeloma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/4l--multiple-myeloma","registrationstatus":""},{"compoundname":"<p><b>arlo-cel<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Multiple Myeloma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/2-4l-multiple-myeloma","registrationstatus":""},{"compoundname":"<p><b>BCL6 LDD<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Lymphoma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma","registrationstatus":""},{"compoundname":"<p><a href='http://packageinserts.bms.com/pi/pi_breyanzi.pdf' title='' class='' target='_blank' aria-label=''><b>BREYANZI<sup>®<\/sup> (lisocabtagene maraleucel)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/registration","researcharea":"<p>Lymphoma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/relapsed-refractory-marginal-zone-lymphoma","registrationstatus":"Registration (US, JP)"},{"compoundname":"<p><b>CD33-GSPT1 ADC<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Leukemia<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/acute-myeloid-leukemia","registrationstatus":""},{"compoundname":"<p><b>Dual Targeting BCMAxGPRC5D CAR T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Multiple Myeloma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/relapsed-refractory-multiple-myeloma","registrationstatus":""},{"compoundname":"<p><b>golcadomide<\/b> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Lymphoma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/1l-follicular-lymphoma","registrationstatus":""},{"compoundname":"<p><b>golcadomide<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lymphoma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/high-risk-1l-large-b-cell-lymphoma","registrationstatus":""},{"compoundname":"<p><b>golcadomide<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lymphoma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/2l--follicular-lymphoma","registrationstatus":""},{"compoundname":"<p><b>HbF Activating CELMoD<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Sickle Cell Disease<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/sickle-cell-disease","registrationstatus":""},{"compoundname":"<p><b>iberdomide<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Multiple Myeloma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/post-autologous-stem-cell-transplant-maintenance-newly-diagnosed-multiple-myeloma","registrationstatus":""},{"compoundname":"<p><b>iberdomide<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p>Multiple Myeloma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/2l--multiple-myeloma","registrationstatus":""},{"compoundname":"<p><b>mezigdomide<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Multiple Myeloma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/2l--multiple-myeloma-vd","registrationstatus":""},{"compoundname":"<p><b>mezigdomide<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p>Multiple Myeloma<\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/2l--multiple-myeloma-kd","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''><b>REBLOZYL<sup>®<\/sup> (luspatercept-aamt)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-2","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/alpha-thalassemia","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''><b>REBLOZYL<sup>®<\/sup> (luspatercept-aamt)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/1l-non-transfusion-dependent-myelodysplastic-syndrome-associated-anemia","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''><b>REBLOZYL<sup>®<\/sup> (luspatercept-aamt)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/1l-transfusion-dependent-myelofibrosis-associated-anemia","registrationstatus":""},{"compoundname":"<p><b>admilparant<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/idiopathic-pulmonary-fibrosis","registrationstatus":""},{"compoundname":"<p><b>admilparant<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/progressive-pulmonary-fibrosis","registrationstatus":""},{"compoundname":"<p><b>BMS-986454<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/rheumatoid-arthritis","registrationstatus":""},{"compoundname":"<p><b>CD19 HD Allo CAR T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/autoimmune-diseases","registrationstatus":""},{"compoundname":"<p><b>CD19 NEX-T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/rheumatoid-arthritis","registrationstatus":""},{"compoundname":"<p><b>CD19 NEX-T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/systemic-sclerosis","registrationstatus":""},{"compoundname":"<p><b>CD19 NEX-T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/idiopathic-inflammatory-myopathies","registrationstatus":""},{"compoundname":"<p><b>CD19 NEX-T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-2","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/systemic-lupus-erythematosus","registrationstatus":""},{"compoundname":"<p><b>obexelimab<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/igg4-related-disease","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''><b>SOTYKTU<sup>®<\/sup> (deucravacitinib)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/systemic-lupus-erythematosus","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''><b>SOTYKTU<sup>®<\/sup> (deucravacitinib)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/sj-gren-s-syndrome","registrationstatus":""},{"compoundname":"<p><b>Anti-MTBR-Tau<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-2","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/alzheimer-s-disease","registrationstatus":""},{"compoundname":"<p><b>BMS-986495<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/neurodegenerative-diseases-","registrationstatus":""},{"compoundname":"<p><b>CD19 NEX-T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/multiple-sclerosis","registrationstatus":""},{"compoundname":"<p><b>CD19 NEX-T<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/myasthenia-gravis","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''><b>COBENFY™<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/adjunctive-bipolar-i-mania","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''><b>COBENFY<sup>™<\/sup><\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/psychosis-in-alzheimer-s-disease","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''><b>COBENFY<sup>™<\/sup><\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/agitation-in-alzheimer-s-disease","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''><b>COBENFY<sup>™<\/sup><\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/alzheimer-s-disease-cognition","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''><b>COBENFY<sup>™<\/sup><\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/bipolar-i-mania","registrationstatus":""},{"compoundname":"<p><b>eIF2B Activator<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/alzheimer-s-disease","registrationstatus":""},{"compoundname":"<p><b>FAAH/MAGL Dual Inhibitor<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-2","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/multiple-sclerosis-spasticity","registrationstatus":""},{"compoundname":"<p><b>FAAH/MAGL Dual Inhibitor<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-2","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/alzheimer-s-disease-agitation","registrationstatus":""},{"compoundname":"<p><b>KarXT Long-Acting Injectable<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/schizophrenia","registrationstatus":""},{"compoundname":"<p><b>TRPC4/5 Inhibitor<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/neuroscience","subcategory":"bms:tumor/mood-and-anxiety-disorders","registrationstatus":""},{"compoundname":"<p><b>Anti-CCR8<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>AR LDD<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p>Prostate Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/metastatic-castration-resistant-prostate-cancer","registrationstatus":""},{"compoundname":"<p><b>atigotatug<\/b> +\n<b>nivolumab<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-extensive-stage-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_augtyro.pdf' title='' class='' target='_blank' aria-label=''><b>AUGTYRO<sup>®<\/sup> (repotrectinib)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/registration","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/nrtk-pan-tumor","registrationstatus":"Registration (JP)"},{"compoundname":"<p><b>BMS-986460<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Prostate Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/prostate-cancer","registrationstatus":""},{"compoundname":"<p><b>BMS-986482<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>BMS-986488<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>BMS-986500<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>BMS-986506<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>BMS-986517<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>pumitamig<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-extensive-stage-small-cell-lung-cancer-","registrationstatus":""},{"compoundname":"<p><b>pumitamig<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-non-small-cell-lung-cancer-","registrationstatus":""},{"compoundname":"<p><b>BMS-986523<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>CD40xFAP Bispecific<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>CEACAM5-TOPO1 ADC<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>iza-bren<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-non-small-cell-lung-cancer-","registrationstatus":""},{"compoundname":"<p><b>pumitamig<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Colorectal Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-microsatellite-stable-colorectal-cancer","registrationstatus":""},{"compoundname":"<p><b>pumitamig<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Gastric Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-gastric-cancer","registrationstatus":""},{"compoundname":"<p><b>iza-bren<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-2","researcharea":"<p>Breast Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-triple-negative-breast-cancer","registrationstatus":""},{"compoundname":"<p><b>iza-bren<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors--","registrationstatus":""},{"compoundname":"<p><b>iza-bren<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/metastatic-non-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><b>pumitamig<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Breast Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-triple-negative-breast-cancer-","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''><b>KRAZATI<sup>®<\/sup> (adagrasib)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Colorectal Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/2l-colorectal-cancer","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''><b>KRAZATI<sup>®<\/sup> (adagrasib)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-non-small-cell-lung-cancer-pd-l1-50-","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''><b>KRAZATI<sup>®<\/sup> (adagrasib)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-non-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><b>nivolumab<\/b> +\n<b>relatlimab HD<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-non-small-cell-lung-cancer-pd-l1-1-","registrationstatus":""},{"compoundname":"<p><b>iza-bren<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/egfr-mutated-post-tki-non-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><b>iza-bren<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Urothelial Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/post-io-metastatic-urothelial-cancer","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf' title='' class='' target='_blank' aria-label=''><b>OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy)<\/b><\/a> +\n<a href='http://packageinserts.bms.com/pi/pi_yervoy.pdf' title='' class='' target='_blank' aria-label=''><b>YERVOY<sup>®<\/sup> (ipilimumab)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-non-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='_blank' aria-label=''><b>OPDIVO<sup>®<\/sup> (nivolumab)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Urothelial Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/peri-adjuvant-muscle-invasive-urothelial-carcinoma","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='_blank' aria-label=''><b>OPDIVO<sup>®<\/sup> (nivolumab)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/phase-3","researcharea":"<p>Hepatocellular Carcinoma<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/adjuvant-hepatocellular-carcinoma","registrationstatus":""},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/2l-non-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-2","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-non-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-2","researcharea":"<p>Pancreatic Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-pancreatic-ductal-adenocarcinoma","registrationstatus":""},{"compoundname":"<p><b>RYZ101<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p>Lung Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/extensive-stage-small-cell-lung-cancer","registrationstatus":""},{"compoundname":"<p><b>RYZ101<\/b> <\/p>","repeat":true,"nmedatastatus":"NME","phaseTag":"bms:phase/phase-1","researcharea":"<p>Breast Cancer<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/hr--her2--unresectable-metastatic-breast-cancer","registrationstatus":""},{"compoundname":"<p><b>RYZ101<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/2l--sstr2--gastroenteropancreatic-neuroendocrine-tumors","registrationstatus":""},{"compoundname":"<p><b>RYZ401<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><b>RYZ801<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Hepatocellular Carcinoma<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/hepatocellular-carcinoma","registrationstatus":""},{"compoundname":"<p><b>subcutaneous nivolumab<\/b> +\n<b>relatlimab<\/b> +\n<b>rHuPH20<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-3","researcharea":"<p>Melanoma<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/1l-melanoma","registrationstatus":""},{"compoundname":"<p><b>WEE1 CELMoD<\/b> <\/p>","repeat":true,"nmedatastatus":"NME Lead","phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors","registrationstatus":""},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''><b>SOTYKTU<sup>®<\/sup> (deucravacitinib)<\/b><\/a> <\/p>","repeat":true,"nmedatastatus":"non-NME","phaseTag":"bms:phase/registration","researcharea":"<p><\/p>","category":"bms:therapeutiic-area/immunology","subcategory":"bms:tumor/psoriatic-arthritis","registrationstatus":"Registration (US, EU, JP)"}],"therapeuticarea":[{"color":"#dbc5c5","name":"bms:therapeutiic-area/cardiovascular","list":[{"name":"bms:tumor/acute-coronary-syndrome--","value":"Acute Coronary Syndrome *"},{"name":"bms:tumor/atrial-fibrillation--","value":"Atrial Fibrillation *"},{"name":"bms:tumor/heart-failure-with-preserved-ejection-fraction","value":"Heart Failure with Preserved Ejection Fraction"},{"name":"bms:tumor/secondary-stroke-prevention--","value":"Secondary Stroke Prevention *"}],"value":"Cardiovascular"},{"color":"#fedcca","name":"bms:therapeutiic-area/hematology","list":[{"name":"bms:tumor/1l-follicular-lymphoma","value":"1L Follicular Lymphoma"},{"name":"bms:tumor/1l-non-transfusion-dependent-myelodysplastic-syndrome-associated-anemia","value":"1L Non-Transfusion Dependent Myelodysplastic Syndrome-Associated Anemia"},{"name":"bms:tumor/1l-transfusion-dependent-myelofibrosis-associated-anemia","value":"1L Transfusion Dependent Myelofibrosis-Associated Anemia"},{"name":"bms:tumor/2-4l-multiple-myeloma","value":"2-4L Multiple Myeloma"},{"name":"bms:tumor/2l--follicular-lymphoma","value":"2L+ Follicular Lymphoma"},{"name":"bms:tumor/2l--multiple-myeloma","value":"2L+ Multiple Myeloma"},{"name":"bms:tumor/2l--multiple-myeloma-kd","value":"2L+ Multiple Myeloma Kd"},{"name":"bms:tumor/2l--multiple-myeloma-vd","value":"2L+ Multiple Myeloma Vd"},{"name":"bms:tumor/4l--multiple-myeloma","value":"4L+ Multiple Myeloma"},{"name":"bms:tumor/acute-myeloid-leukemia","value":"Acute Myeloid Leukemia"},{"name":"bms:tumor/alpha-thalassemia","value":"Alpha-Thalassemia"},{"name":"bms:tumor/high-risk-1l-large-b-cell-lymphoma","value":"High Risk 1L Large B-cell Lymphoma"},{"name":"bms:tumor/lymphoma","value":"Lymphoma"},{"name":"bms:tumor/post-autologous-stem-cell-transplant-maintenance-newly-diagnosed-multiple-myeloma","value":"Post-Autologous Stem Cell Transplant Maintenance Newly Diagnosed Multiple Myeloma"},{"name":"bms:tumor/relapsed-refractory-marginal-zone-lymphoma","value":"Relapsed/Refractory Marginal Zone Lymphoma"},{"name":"bms:tumor/relapsed-refractory-multiple-myeloma","value":"Relapsed/Refractory Multiple Myeloma"},{"name":"bms:tumor/sickle-cell-disease","value":"Sickle Cell Disease"}],"value":"Hematology"},{"color":"#c5ffe6","name":"bms:therapeutiic-area/immunology","list":[{"name":"bms:tumor/autoimmune-diseases","value":"Autoimmune Diseases"},{"name":"bms:tumor/idiopathic-inflammatory-myopathies","value":"Idiopathic Inflammatory Myopathies"},{"name":"bms:tumor/idiopathic-pulmonary-fibrosis","value":"Idiopathic Pulmonary Fibrosis"},{"name":"bms:tumor/igg4-related-disease","value":"IgG4-Related Disease"},{"name":"bms:tumor/progressive-pulmonary-fibrosis","value":"Progressive Pulmonary Fibrosis"},{"name":"bms:tumor/psoriatic-arthritis","value":"Psoriatic Arthritis"},{"name":"bms:tumor/rheumatoid-arthritis","value":"Rheumatoid Arthritis"},{"name":"bms:tumor/sj-gren-s-syndrome","value":"Sjögren's Syndrome"},{"name":"bms:tumor/systemic-lupus-erythematosus","value":"Systemic Lupus Erythematosus"},{"name":"bms:tumor/systemic-sclerosis","value":"Systemic Sclerosis"}],"value":"Immunology"},{"color":"#d8ddd1","name":"bms:therapeutiic-area/neuroscience","list":[{"name":"bms:tumor/adjunctive-bipolar-i-mania","value":"Adjunctive Bipolar-I Mania"},{"name":"bms:tumor/agitation-in-alzheimer-s-disease","value":"Agitation in Alzheimer's Disease"},{"name":"bms:tumor/alzheimer-s-disease","value":"Alzheimer's Disease"},{"name":"bms:tumor/alzheimer-s-disease-agitation","value":"Alzheimer's Disease Agitation"},{"name":"bms:tumor/alzheimer-s-disease-cognition","value":"Alzheimer's Disease Cognition"},{"name":"bms:tumor/bipolar-i-mania","value":"Bipolar-I Mania"},{"name":"bms:tumor/mood-and-anxiety-disorders","value":"Mood and Anxiety Disorders"},{"name":"bms:tumor/multiple-sclerosis","value":"Multiple Sclerosis"},{"name":"bms:tumor/multiple-sclerosis-spasticity","value":"Multiple Sclerosis Spasticity"},{"name":"bms:tumor/myasthenia-gravis","value":"Myasthenia Gravis"},{"name":"bms:tumor/neurodegenerative-diseases-","value":"Neurodegenerative Diseases*"},{"name":"bms:tumor/psychosis-in-alzheimer-s-disease","value":"Psychosis in Alzheimer's Disease"},{"name":"bms:tumor/schizophrenia","value":"Schizophrenia"}],"value":"Neuroscience"},{"color":"#c0f2fb","name":"bms:therapeutiic-area/oncology","list":[{"name":"bms:tumor/1l-extensive-stage-small-cell-lung-cancer","value":"1L Extensive-Stage Small Cell Lung Cancer"},{"name":"bms:tumor/1l-extensive-stage-small-cell-lung-cancer-","value":"1L Extensive-Stage Small Cell Lung Cancer*"},{"name":"bms:tumor/1l-gastric-cancer","value":"1L Gastric Cancer"},{"name":"bms:tumor/1l-melanoma","value":"1L Melanoma"},{"name":"bms:tumor/1l-microsatellite-stable-colorectal-cancer","value":"1L Microsatellite Stable Colorectal Cancer"},{"name":"bms:tumor/1l-non-small-cell-lung-cancer","value":"1L Non-Small Cell Lung Cancer"},{"name":"bms:tumor/1l-non-small-cell-lung-cancer-","value":"1L Non-Small Cell Lung Cancer*"},{"name":"bms:tumor/1l-non-small-cell-lung-cancer-pd-l1-1-","value":"1L Non-Small Cell Lung Cancer PD-L1≥1%"},{"name":"bms:tumor/1l-non-small-cell-lung-cancer-pd-l1-50-","value":"1L Non-Small Cell Lung Cancer PD-L1≥50%"},{"name":"bms:tumor/1l-pancreatic-ductal-adenocarcinoma","value":"1L Pancreatic Ductal Adenocarcinoma"},{"name":"bms:tumor/1l-triple-negative-breast-cancer","value":"1L Triple-Negative Breast Cancer"},{"name":"bms:tumor/1l-triple-negative-breast-cancer-","value":"1L Triple-Negative Breast Cancer*"},{"name":"bms:tumor/2l--sstr2--gastroenteropancreatic-neuroendocrine-tumors","value":"2L+ SSTR2+ Gastroenteropancreatic Neuroendocrine Tumors"},{"name":"bms:tumor/2l-colorectal-cancer","value":"2L Colorectal Cancer"},{"name":"bms:tumor/2l-non-small-cell-lung-cancer","value":"2L Non-Small Cell Lung Cancer"},{"name":"bms:tumor/adjuvant-hepatocellular-carcinoma","value":"Adjuvant Hepatocellular Carcinoma"},{"name":"bms:tumor/egfr-mutated-post-tki-non-small-cell-lung-cancer","value":"EGFR-mutated Post-TKI Non-Small Cell Lung Cancer"},{"name":"bms:tumor/extensive-stage-small-cell-lung-cancer","value":"Extensive-Stage Small Cell Lung Cancer"},{"name":"bms:tumor/hepatocellular-carcinoma","value":"Hepatocellular Carcinoma "},{"name":"bms:tumor/hr--her2--unresectable-metastatic-breast-cancer","value":"HR+/HER2- Unresectable Metastatic Breast Cancer"},{"name":"bms:tumor/metastatic-castration-resistant-prostate-cancer","value":"Metastatic Castration-Resistant Prostate Cancer"},{"name":"bms:tumor/metastatic-non-small-cell-lung-cancer","value":"Metastatic Non-Small Cell Lung Cancer"},{"name":"bms:tumor/nrtk-pan-tumor","value":"NRTK Pan-Tumor"},{"name":"bms:tumor/peri-adjuvant-muscle-invasive-urothelial-carcinoma","value":"Peri-adjuvant Muscle-Invasive Urothelial Carcinoma"},{"name":"bms:tumor/post-io-metastatic-urothelial-cancer","value":"Post-IO Metastatic Urothelial Cancer"},{"name":"bms:tumor/prostate-cancer","value":"Prostate Cancer"},{"name":"bms:tumor/solid-tumors","value":"Solid Tumors"},{"name":"bms:tumor/solid-tumors--","value":"Solid Tumors *"}],"value":"Oncology"}],"subCategoryColor":"#A69F9F"}
Please click on product name to see the Full U.S. Prescribing Information for AUGTYRO®, BREYANZI®, COBENFY™, KRAZATI®, OPDIVO®, OPDIVO QVANTIG™, REBLOZYL®, SOTYKTU® and YERVOY® including Boxed WARNINGS for BREYANZI®.
Development Partnerships: Anti-CCR8 + nivolumab, nivolumab + relatlimab HD, OPDIVO, YERVOY: Ono; AUGTYRO, COBENFY (KarXT): Zai Lab; BMS-986495: Prothena; pumitamig (BNT327/BMS-986545): BioNTech; iza-bren: SystImmune; milvexian: Johnson & Johnson; obexelimab: Zenas BioPharma; REBLOZYL: Merck; rHuPH20: Halozyme
Reference notes:
* Partner-run study
(NME) New Molecular Entity Lead Indication
For information on approved uses, refer to approved product labeling. Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study. Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.